Синтез наркотиков [A] · изменено

DMT. Part II. Clinical effects, doses, studies (continuation)

As a Schedule I controlled substance, DMT can be seen as an addictive substance, associated with substantial health risks. Notwithstanding, studies have been contradicting this, as no compulsive drug‐seeking precipitated by consumption of DMT or ayahuasca has been reported in humans. Psychedelics, including DMT and ayahuasca, are, in fact, seen as safer substances than cocaine, opiates, or even the widely used nicotine and alcohol, with the advantage of lacking the abuse potential, characteristic of these former drugs. As reviewed by Gable et al., reports of abstinence syndrome after termination of DMT consumption are unknown. Studies with repeated administration of DMT to volunteers have seen little or no drug tolerance. Comparing long‐term users and occasional consumers of ayahuasca, Bouso et al. found that following ingestion of a single dose, both groups were associated with lower scores on working memory and performance improvement, but only the occasional users had an impaired performance in strategic planning. Thus, greater prior exposure to ayahuasca by long‐term users was associated with drug‐induced neuromodulatory or compensatory effects, resulting in reduced cognitive incapacitation. Further, reports on tolerance solely included slight changes in the release of growth hormone, adrenocorticotropic hormone, and prolactin, which were found to be decreased following a second administration, and lower response in the systolic blood pressure and heart rate. DMT did not elicit tolerance in animal models like squirrel monkeys and cats. Additionally, LSD is not capable to produce cross‐tolerance to DMT, contrary to what happens with other classic hallucinogens like mescaline or psilocybin. The absence of cross‐tolerance suggests a distinguished pharmacodynamic behaviour for DMT, which makes it a quite unique substance among classic hallucinogens.
Documentaries and videos:
Home to the Centre for Psychedelic Research headed by psychedelic researcher Dr Robin Carhart-Harris, Imperial College London has been at the forefront of modern psychedelic research. The center’s clinical research focuses on the therapeutic potential of psychedelics like DMT and psilocybin for major depression.
ICL Depression Study: in collaboration with the neuropharmaceutical company Small Pharma, Imperial College London researchers are conducting the world’s first clinical trial for DMT this year. The first phase of the trial is planned to start this month, with the initial aim of evaluating the effects of DMT-assisted therapy in healthy volunteers. The subsequent PhaseIIa trial will evaluate the efficacy of the treatment in patients with Major Depressive Disorder (MDD).
University Hospital of Basel in Basel, Switzerland, is home to the Liechti lab, a leading psychedelic research group that investigates the effects and pharmacological action of DMT and other psychedelics.
Effects of Dimethyltryptamine in Healthy Subjects (DMT): Researchers in the Liechti Lab at University Hospital of Basel are collaborating with the psychedelic biotech company MindMed to evaluate the effects of different DMT dosing regimens in 30 healthy participants. This Phase I clinical trial was announced in June of 2020 and expected to begin in the fourth quarter of 2020.
Research from 2013 led by Dr. Gerald Thomas at the University of Victoria, Canada, investigated how ayahuasca therapy can lead to long-term improvements in addiction outcomes. This research has set the stage for further research to investigate ayahuasca-assisted therapy for addiction treatment, and to confirm their promising findings.
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada: Co-funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), this observational study examined the safety and efficacy of ayahuasca for treating addiction and dependence. Six months after the five-day ayahuasca retreat, the researchers found that the 12 participants sustained significant improvements in life meaning, empowerment, mindfulness, and hopefulness, as well as reductions in drug and alcohol use.
From 1990 to 1995, Dr. Rick Strassman conducted groundbreaking clinical research on DMT at the University of New Mexico. After a decades-long hiatus from psychedelic research nationwide, Dr. Strassman revived these studies by intravenously administering 400 doses of N,N-DMT to 60 volunteers and documenting the experiences and therapeutic potential of the sessions. The results from these studies cumulated into a book entitled DMT: The Spirit Molecule.
Established in 2019, JHU’s Center for Psychedelic and Consciousness Research is dedicated to understanding how psychedelics affect behavior, mood, cognition, brain function, and outcomes for disorders like depression, PTSD, and substance use disorder.
DMT: The Spirit Molecule: A Doctor’s Revolutionary Research Into the Biology of Near-Death and Mystical Experiences by Rick Strassman.
DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible by Rick Strassman.
DMT Dialogues: Encounters with the Spirit Molecule by David Luke.
Mystery School in Hyperspace: A Cultural History of DMT by Graham St. John.
DMT & My Occult Mind—LITE: Investigation of Occult Realities Using the Spirit Molecule by Dick Khan.
DMT: The Spirit Molecule—A 2010 documentary exploring Dr. Rick Strassman’s research on DMT at the University of New Mexico in the 1990s.
DMT: A Religious Model with Rick Strassman, M.D.—A 2015 talk given by Dr. Rick Strassman at the National Psychedelic Symposium at CU Boulder introducing a theistic model of the DMT experience.
DMT: A Lost History—A 2015 documentary exploring the use of DMT-containing plants throughout the ancient world.
Terence McKenna—Everything You Need to Know About DMT—Terence McKenna describing DMT and his experiences in hyperspace with machine elves.
Neurons to Nirvana—A 2013 documentary film by Canadian filmmaker Oliver Hockenhull that traces the history and therapeutic potential of five psychedelics, including DMT.
Aya: Awakenings—A 2013 documentary on ayahuasca and Amazonian shamanism adapted from Rak Razam’s book, Aya: A Shamanic Odyssey.
From Shock to Awe—This 2018 documentary by Luc Côté and Janine Sagert follows the healing journey of two combat veterans suffering from PTSD. Finding pharmaceuticals ineffective, they turn to entheogens like ayahuasca for deeper healing.
Terence McKenna’s True Hallucinations—A 2016 experimental documentary on Terence McKenna’s adventures and psychedelic experiences in La Chorrera, Panama with his brother Dennis McKenna.
The Last Shaman—A 2016 Netflix movie that documents a clinically-depressed young man’s journey into the Amazon, where he encounters the deep healing properties of ayahuasca.
Shamans of the Amazon—A Timeless Journey—A 2016 documentary by Dean Jefferys exploring Amazonian shamanism, ayahuasca rituals, and indigenous spirituality.
Wizards of DMT—Season 2, Episode 4 of the docuseries Hamilton’s Pharmacopeia. The episode follows Hamilton Morris’s journey across North America, as he discovers why and how DMT is present in the laboratory and naturally in the environment.
Inside a Home DMT Lab Run by A Chemistry Teacher | High Society—Vice explores how DMT is made at the home of an anonymous chemistry teacher named “Bob”.
Psychedelic Support Network—A list curated by Psychedelic Support of credentialed integration therapists offering services, such as pre- and post-ritual counseling and individual and group psychedelic integration.
Mystery School in Hyperspace is the first book to delve into the history of this substance, the discovery of its properties, and the impact it has had on poets, artists, and musicians.
DMT and the Mainstreaming of Psychedelics.
It is a hub and information point for users of DMT and ayahuasca; a place for those interested to find out about the latest news and events, conduct research, and read, share and discuss all aspects of their experiences with likeminded people.
This is a compilation of reports of using N,N-dimethyltryptamine (DMT), usually by smoking, mostly derived from a compilation by a person named "Pup" which was posted in 2005-2006 to the dmt.tribe.net website as DMT trip accounts.
The body of work entitled “Entities” was created between 2014 and 2018. These observational illustrations depict seemingly autonomous beings, from mysteriously sensed encounters. The production of this series is ongoing.
ATAI launches Viridia Life Sciences to develop novel formulations of N, N-Dimethyltryptamine (DMT) for a range of mental health conditions.
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects.
Effects of Dimethyltryptamine in Healthy Subjects (DMT).
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans.
Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain.
'Mystical' psychedelic compound found in normal brains of rats.
A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.
DMT Models the Near-Death Experience.
Phenomenology of N,N-Dimethyltryptamine Use: A Thematic Analysis.
A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
Discarnate entities and dimethyltryptamine (DMT): Psychopharmacology, phenomenology and ontology.
So long as you’ve got your elf: Death, DMT and discarnate entities.
Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression.
Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Psychedelics Promote Structural and Functional Neural Plasticity.
N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo.
Neural correlates of the DMT experience assessed with multivariate EEG.
N,N-dimethyltryptamine facts and myths.
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging.
Below are some of the most recommended DMT retreat centers:

Arkana Spiritual Center in Iquitos, Peru - https://www.arkanainternational.com/

The Healing Tree Center in Cusco, Peru - https://healingtreeayahuasca.com/

Dreamglade in Iquitos, Peru - https://www.dreamglade.com/

Spirit Vine Ayahuasca Retreat Center in Itacaré, Brazil - https://spiritvineretreats.com/

Nada Brahma Healing Center in Alajuela, Costa Rica - https://nadabrahmahealingcenter.com/

Gaia Sagrada in Cuenca, Ecuador - https://gaiasagrada.com/

Источник: http://bbzzzsvqcrqtki6umym6itiixfhni37ybtt7mkbjyxn2pgllzxf2qgyd.onion/threads/dmt-part-ii-clinical-effects-doses-studies.540/

↑ 5

Обсуждение

Комментарии

3

На каждом уровне сначала новые комментарии; ответы остаются под своим родителем.

Написать Join — чтобы участвовать в обсуждении.

this is actually very interesting , psychedelics , especially in this category have been known as not being addictive. I personally was always under that same assumption. Definitely doing my research lol.

the no-cross-tolerance with lsd bit is the one that keeps nagging at me. if tolerance is mostly 5-ht2a downregulation, dmt of all things should show it, so the pharmodynamics must differ more than the receptor label suggests.
the no-cross-tolerance thing with lsd is the bit that always gets me. most classic hallucinogens step on each other's toes fast, dmt just doesn't play that game. quietly makes it a odd one out in the whole class.